Microenvironment-dependent growth of pre-neoplastic and malignant plasma cells in humanized mice

[1]  A. Burls.  Critical appraisal , 2016, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.

[2]  M. Dhodapkar,et al.  Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. , 2016, The New England journal of medicine.

[3]  Mustafa Saad,et al.  Implications for Therapy , 2016 .

[4]  A. Zannettino,et al.  Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche , 2015, Nature Communications.

[5]  J. Crowley,et al.  Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. , 2015, Blood.

[6]  M. Dhodapkar,et al.  Immune Modulation in Hematologic Malignancies. , 2015, Seminars in oncology.

[7]  M. Dhodapkar,et al.  Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. , 2015, Blood.

[8]  M. Wunderlich,et al.  Xenograft models for normal and malignant stem cells. , 2015, Blood.

[9]  R. Siliciano,et al.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations , 2015, Nature.

[10]  N. Potter,et al.  Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma , 2014, Leukemia.

[11]  Christopher A. Miller,et al.  Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. , 2014, Cancer cell.

[12]  A. Palucka,et al.  Development and function of human innate immune cells in a humanized mouse model , 2014, Nature Biotechnology.

[13]  S. Mane,et al.  Serial exome analysis of disease progression in premalignant gammopathies , 2014, Leukemia.

[14]  B. Barlogie,et al.  Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). , 2014, Blood.

[15]  Lisa J. Murray,et al.  Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms , 2013, Leukemia.

[16]  R. Wäsch,et al.  Preclinical models of multiple myeloma: a critical appraisal , 2013, Expert opinion on biological therapy.

[17]  R. Flavell,et al.  Human hemato-lymphoid system mice: current use and future potential for medicine. , 2013, Annual review of immunology.

[18]  T. Boggon,et al.  Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma , 2013, Proceedings of the National Academy of Sciences.

[19]  I. Weissman,et al.  CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells , 2012, Leukemia.

[20]  M. Hino,et al.  CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients , 2012, Leukemia.

[21]  I. Ghobrial,et al.  Myeloma as a model for the process of metastasis: implications for therapy. , 2012, Blood.

[22]  D. Schatz,et al.  Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma. , 2012, Blood.

[23]  S. Mane,et al.  K+ Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension , 2011, Science.

[24]  N. Munshi,et al.  A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells , 2011, Leukemia.

[25]  N. Gutiérrez,et al.  The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells , 2010, Clinical Cancer Research.

[26]  J. Crowley,et al.  Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy , 2007, The Journal of experimental medicine.

[27]  Yongsheng Huang,et al.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.

[28]  S. Jagannath,et al.  Enhancement of clonogenicity of human multiple myeloma by dendritic cells , 2006, The Journal of experimental medicine.

[29]  Pierfrancesco Tassone,et al.  A clinically relevant SCID-hu in vivo model of human multiple myeloma. , 2004, Blood.

[30]  T. Kishimoto.  Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.

[31]  C. Huff,et al.  Characterization of clonogenic multiple myeloma cells. , 2004, Blood.

[32]  M. Dhodapkar,et al.  Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy , 2003, The Journal of experimental medicine.

[33]  M. Dhodapkar,et al.  A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma , 2003, The Journal of experimental medicine.

[34]  B. Barlogie,et al.  Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. , 1998, Blood.

[35]  S. Akira,et al.  Interleukin-6 and its receptor: a paradigm for cytokines. , 1992, Science.

[36]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.